Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.
InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.
Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy.
